Evidence map›Paper›PMID 31399115›Full record

ArticleRadiation oncology (London, England)2019

A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma.

Sergiu Scobioala, Christopher Kittel, Khaled Elsayad, Kai Kroeger, Michael Oertel, Laith Samhouri, Uwe Haverkamp, Hans Theodor Eich

Abstract readComparative Study
In one paragraph

Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sergiu ScobioalaDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany. sscobioala@yahoo.com.ORCID http://orcid.org/0000-0001-9622-3169
Christopher KittelDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany.
Khaled ElsayadDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany.
Kai KroegerDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany.
Michael OertelDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany.
Laith SamhouriDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany.
Uwe HaverkampDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany.
Hans Theodor EichDepartment of Radiation Oncology of the University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebäude 1, 48149, Muenster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeComparing radiation treatment plans by using the same safety margins and dose objectives for all techniques, to ascertain the optimal radiation technique for the stereotactic body radiotherapy (SBRT) of low-risk prostate cancer. MATERIAL AND

methodsTreatment plans for 27 randomly selected patients were compared using intensity-modulated (IMRT) techniques as Sliding Window (SW), volumetric modulated arc therapy (VMAT), and helical tomotherapy (HT), as well as Cyber Knife (CK) system. The target dose was calculated to 36.25 Gy delivered in five fractions over 1 week. Dosimetric indices for target volume and organs at risk (OAR) as well as normal tissue complication probability (NTCP) of late rectal and urinary bladder toxicities were analyzed.

resultsThe CK provided lower homogeneity in the target volume, but higher values for most of the conformity indices compared to the IMRT approaches. The SW demonstrated superior rectum sparing at medium-to-high dose range (V18 Gy - V32.6 Gy) compared to other techniques (p < 0.05). The whole urinary bladder experienced the best shielding by SW and VMAT at the medium dose (V18 Gy, p < 0.05 versus CK), however we obtained no relevant differences between techniques at the high dose. Generally, the CK demonstrated significantly superior rectum and bladder exposure at V18 Gy as compared to HT, SW, and VMAT. For the rectum, mean NTCP values were significantly superior for HT (NTCP = 2.3%, p < 0.05), and for urinary bladder, the NTCP showed no significant advantages for any technique.

conclusionNo absolute dosimetric advantage was revealed to choose between CK or IMRT techniques for the SBRT of low-grade prostate cancer. Using the same safety margins and dose objectives, IMRT techniques demonstrated superior sparing of the rectum and bladder at a medium dose compared to CK. Comparing different IMRT approaches SW displayed superior rectum sparing at a medium-to-high dose range, whereas both SW and RA revealed superior bladder sparing compared to HT. HT demonstrated a significantly lower NTCP outcome compared to CK or IMRT techniques regarding the rectum. Radiation plans can be optimized further by an individual modification of dose objectives independent of the treatment plan strategy.

Indexed as

AgedHumansMaleMiddle AgedOrgans at RiskPrognosisProstatic NeoplasmsRadiosurgeryRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedRandom AllocationRetrospective StudiesRisk FactorsCyber knifeDosimetric indicesIntensity-modulated radiotherapyNormal tissue complication probabilityProstate carcinomaStereotactic radiotherapy

Identifiers

PMID31399115
PMCPMC6689170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.